News Feature: Avacopan for ANCA Vasculitis Goes in Front of the FDA An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for ANCA-associated vasculitis. https://t.co/66NSjbkE8Q https://t.co/9cR2lBASjz